Privately-held Swiss biotech firm MaxiVAX SA has appointed Dimitrios Goundis as its chief executive. Dr Goundis joins the company after holding several senior management and R&D positions at The Medicines Company, Speedel and Roche, both in Europe and the USA. 8 February 2016
French drug major Sanofi on Friday named Muzammil Mansuri executive vice president, strategy & business development, effective February 22, 2016. 5 February 2016
Gilead Sciences Inc on Friday said chief operating officer John Milligan will be promoted to chief executive, replacing the current chairman and CEO John Martin who will take on the role of executive chairman, both effective March 10, 2016. 29 January 2016
Swiss pharma major Novartis, along with its financial results (see separate story) this morning, announced a major changes for its underperforming ophthalmic business Alcon, as well as some senior management appointments. 27 January 2016
Germany’s Merck on Wednesday announced two appointments to head its businesses in North America and China in a bid to strengthen its position in the regions. 27 January 2016
Valeant Pharmaceuticals’ chief executive Michael Pearson has said he is on the road to recovery but that he was uncertain about when he would return from medical leave. 26 January 2016
Germany's Merck KGaA said it has appointed Jessie English as the vice president of discovery, translational innovation platform immuno-oncology, effective February 16, 2016. 21 January 2016
Austria-based biotechnology company Themis Bioscience on Tuesday announced the appointment of two new members to leadership roles, Philippe Dro and Christian Mandl. 19 January 2016
UK biotech firm Centauri Therapeutics said today it has acquired the Alphamer technology for drug discovery and development from Altermune Technologies. 18 January 2016
Swedish Orphan Biovitrum today announced that Birgitte Volck, senior vice president of development and chief medical officer (CMO) of Sobi, will leave the company. 14 January 2016
Shares in US biotech firm Celgene Corp closed down over 5.5% on Nasdaq Monday after the company named chief operating officer Mark Alles as chief executive effective March 1, and cut its outlook for 2015. 12 January 2016
Switzerland-based Cardiorentis AG said it has raised 60 million Swiss Franc ($60 million) via private investors to advance its Phase III trials for Ularitide, a therapy for acute decompensated heart failure (ADHF), including upcoming regulatory submissions expected in the second half of 2016. 11 January 2016
Cytos Biotechnology on Friday said the company will be renamed Kuros Biosciences Ltd and that its chief executive Christian Itin will be stepping down from his position. 8 January 2016
Allogeneic CAR T-cell therapies specialist Cellectis has announced the appointment of Loan Hoang-Sayag to the role of chief medical officer. 8 January 2016
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024